<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397397</url>
  </required_header>
  <id_info>
    <org_study_id>15/2006CTIL</org_study_id>
    <nct_id>NCT00397397</nct_id>
  </id_info>
  <brief_title>Comparative Treatment Study in Patients With Lower Ureteral Stones</brief_title>
  <official_title>Comparative Study in Patients With Lower Ureteral Stones Treated With 10 MG Alfuzosin,10 MG Alfuzosin With Rowatinex, and Rowatinex Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <brief_summary>
    <textblock>
      We wish to determine the best treatment for expulsion of lower ureteral stones. Which of the&#xD;
      three major treatment protocols is the best treatment of conservative management of ureteral&#xD;
      stones?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 60 patients with lower ureteral stones. The patients will be divided&#xD;
      into three groups. The first group will be administered Alfuzosin (10 mg). The second group&#xD;
      will be administered a combination of Alfuzosin (10 mg)and Rowatinex (Pinene 31%, Camphene&#xD;
      15%, Anetol 4%, Borneol 10%, Cineol 3%, Fenchenol 4%, Olive Oil 33%). The third group will be&#xD;
      administered Rowatinex.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date>March 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>Urinary Calculi</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of lower ureter (urinary calculi) up to 8mm&#xD;
&#xD;
          -  Must be able to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sensitivity to Alfuzosin and Rowatinex&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
          -  Single kidney&#xD;
&#xD;
          -  Obstructing stone&#xD;
&#xD;
          -  Renal failure creatinine up to 1.8 mg/dl&#xD;
&#xD;
          -  Patients using various alpha blockers&#xD;
&#xD;
          -  Liver failure&#xD;
&#xD;
          -  Fever higher than 38 C&#xD;
&#xD;
          -  UTI&#xD;
&#xD;
          -  Syncope or hypotension&#xD;
&#xD;
          -  Patients treated with PDE5&#xD;
&#xD;
          -  Patients treated with inhibitor CYP3A4&#xD;
&#xD;
          -  Patients refusing participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Faragi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology Department, Hillel Yaffe Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>November 8, 2006</study_first_submitted>
  <study_first_submitted_qc>November 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>November 8, 2006</last_update_submitted>
  <last_update_submitted_qc>November 8, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2006</last_update_posted>
  <keyword>Urinary Calculi</keyword>
  <keyword>Rowatinex</keyword>
  <keyword>Alfuzosin</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

